These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7771328)

  • 1. 5-Lipoxygenase activating protein and leukotriene C4 synthase: therapeutic targets for inhibiting the leukotriene cascade.
    Ford-Hutchinson AW
    Adv Prostaglandin Thromboxane Leukot Res; 1994; 22():13-21. PubMed ID: 7771328
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.
    Gupta N; Nicholson DW; Ford-Hutchinson AW
    Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukotriene C4 synthase and 5-lipoxygenase activating protein. Regulators of the biosynthesis of sulfido-leukotrienes.
    Ford-Hutchinson AW
    Ann N Y Acad Sci; 1994 Nov; 744():78-83. PubMed ID: 7825864
    [No Abstract]   [Full Text] [Related]  

  • 4. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis.
    Ago H; Kanaoka Y; Irikura D; Lam BK; Shimamura T; Austen KF; Miyano M
    Nature; 2007 Aug; 448(7153):609-12. PubMed ID: 17632548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis.
    Bäck M
    Curr Pharm Des; 2009; 15(27):3116-32. PubMed ID: 19754386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of leukotriene biosynthesis.
    Ford-Hutchinson AW
    Cancer Metastasis Rev; 1994 Dec; 13(3-4):257-67. PubMed ID: 7712588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Lipoxygenase activating protein (ALOX5AP): association with cardiovascular infarction and stroke.
    Ben-Asher E; Lancet D
    Isr Med Assoc J; 2004 May; 6(5):318-9. PubMed ID: 15151378
    [No Abstract]   [Full Text] [Related]  

  • 8. Summary: the enzymes, accessory proteins, and receptors of leukotriene metabolism and their inhibition and antagonism.
    Dennis EA; Krell RD
    Adv Prostaglandin Thromboxane Leukot Res; 1994; 22():63-7. PubMed ID: 7771350
    [No Abstract]   [Full Text] [Related]  

  • 9. Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591.
    Tagari P; Becker A; Brideau C; Frenette R; Sadl V; Thomas E; Vickers P; Ford-Hutchinson A
    J Pharmacol Exp Ther; 1993 Apr; 265(1):416-25. PubMed ID: 8386242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart disease. Gene suggests asthma drugs may ease cardiovascular inflammation.
    Wickelgren I
    Science; 2004 Feb; 303(5660):941. PubMed ID: 14963296
    [No Abstract]   [Full Text] [Related]  

  • 11. Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein.
    Strid T; Svartz J; Franck N; Hallin E; Ingelsson B; Söderström M; Hammarström S
    Biochem Biophys Res Commun; 2009 Apr; 381(4):518-22. PubMed ID: 19233132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.
    Evans JF; Lévillé C; Mancini JA; Prasit P; Thérien M; Zamboni R; Gauthier JY; Fortin R; Charleson P; MacIntyre DE
    Mol Pharmacol; 1991 Jul; 40(1):22-7. PubMed ID: 1857337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLAP: a novel drug target for inhibiting the synthesis of leukotrienes.
    Ford-Hutchinson AW
    Trends Pharmacol Sci; 1991 Feb; 12(2):68-70. PubMed ID: 2024291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the biosynthesis of the sulphido-leukotrienes.
    Ford-Hutchinson AW
    Adv Exp Med Biol; 1997; 400B():841-7. PubMed ID: 9547637
    [No Abstract]   [Full Text] [Related]  

  • 15. Activation of leukotriene production in granulocytes: effects on cell activation.
    Ford-Hutchinson AW
    Immunol Ser; 1992; 57():87-106. PubMed ID: 1504152
    [No Abstract]   [Full Text] [Related]  

  • 16. 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.
    Mancini JA; Prasit P; Coppolino MG; Charleson P; Leger S; Evans JF; Gillard JW; Vickers PJ
    Mol Pharmacol; 1992 Feb; 41(2):267-72. PubMed ID: 1538707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases.
    Evans JF; Ferguson AD; Mosley RT; Hutchinson JH
    Trends Pharmacol Sci; 2008 Feb; 29(2):72-8. PubMed ID: 18187210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Lipoxygenase.
    Ford-Hutchinson AW; Gresser M; Young RN
    Annu Rev Biochem; 1994; 63():383-417. PubMed ID: 7979243
    [No Abstract]   [Full Text] [Related]  

  • 19. Leukotriene biosynthetic enzymes as therapeutic targets.
    Haeggström JZ
    J Clin Invest; 2018 Jul; 128(7):2680-2690. PubMed ID: 30108195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of indolylalkoxyiminoalkylcarboxylates as leukotriene biosynthesis inhibitors.
    Kolasa T; Bhatia P; Brooks CD; Hulkower KI; Bouska JB; Harris RR; Bell RL
    Bioorg Med Chem; 1997 Mar; 5(3):507-14. PubMed ID: 9113329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.